Skip to main content

Advertisement

Table 2 Clinical and pathological variables in young breast cancer patients (N = 144) and their associations with disease progression (HR hazard ratio, CI confidence interval)

From: Pathological profiles and clinical management challenges of breast cancer emerging in young women in Indonesia: a hospital-based study

Variables N % HR (95%CI)
The family history of breast cancer
 No 133 92.40% 0.969 (0.258–3.640)
 Yes 11 7.60% ref
Parity
 Nulliparity 17 11.80% 1.925 (0.647–5.730)
 Multiparity 127 88.20% ref
Chief presentation
 Breast lump 94 65.30% 1.295 (0.6–2.795)
 Skin induration or lesion 37 25.70% ref
 Axillary mass 4 2.80%
 Pain 9 6.30%
Positive biopsy diagnosis
 Fine needle aspiration 82 56.90% N/A
 Biopsy 62 43.10% N/A
Localization
 Right 68 47.20% 3.839 (1.045–14.112)
 Left 51 39.60%
 Bilateral 19 13.20% ref
Multifocal lumps
 No 118 82% 3.839 (1.045–14.112)
 Yes 26 18% ref
Tumor size
 Median 5.5 cm   
  > 3 121 84% 3.8 (1.04–14.11)
  ≤ 3 23 16% ref
Lymph node involvement
 positive 108 75% 2.159 (0.912–5.108)
 negative 36 25.00% ref
Stage
 I 5 3.50% ref
 II 47 32.60%
 III 69 47.900% 0.610 (0.278–1.339)
 IV 23 16%
Distant metastasis at diagnosis
 Yes 23 16% 8.627 (1.909–38.994)
 No 121 84% ref
Histology
 Ductal 117 81.30% 1.568 (0.289–8.501)
 Lobular 12 8.30% ref
 Ductolobuler 8 5.60%
 Others 7 4.80%
mSBR grading
 I 1 0.70% 0.836 (0.334–2.092)
 II 30 20.80%
 III 113 78.50% ref
Angioinvasion
 No 6 4.20% 0.761 (0.134–4.335)
 Yes 138 95.80% ref
Lymphatic invasion
 No 14 9.70% 2.513 (0.668–9.447)
 Yes 130 90.30% ref
Hormonal receptor
 Negative 86 59.70% 1.6 (0.753–3.398)
 Positive 57 39.60% ref
HER2 expression
 Negative 99 68.80% 0.623 (0.281–1.382)
 Positive 44 30.60% ref
Molecular classification
 Triple Negative 55 38.20% 2.209 (0.945–5.162)
 Luminal 62 43.10% ref
 HER2 26 18.10%